Our retrospective study aims to evaluate the association of anti-calcitonin gene-related peptide (CGRP) and its receptor (CGRPR) monoclonal antibodies (mAbs) treatment with headache frequency and severity in the pediatric migraine population.

Migraine headaches are commonly diagnosed in the pediatric population and increases in prevalence over the course of adolescence. Currently, topiramate remains the only FDA-labelled treatment of headache prevention in adolescents between ages 12-17.

In recent years, several anti-CGRP and anti-CGRPR mAbs have been approved for migraine prevention in adults. None of these agents are approved in children and limited data exists regarding their use and efficacy. 

The study population includes pediatric patients between the ages of 10-17 with history of migraine headaches, previously or currently receiving an anti-CGRP or anti-CGRPR mAb agent. The clinical database at Phoenix Children’s Hospital is used to identify patients currently receiving or having received any of the following anti-CGRP or anti-CGRPR mAbs: erenumab, fremanezumab, or galcanezumab. Chart review was conducted to identify headache frequency and severity pre- and post-treatment as well as common adverse effects.

The study is in completing stages of data collection and analyzation, however, preliminary results indicate a small reduction in monthly headache days and overall headache severity. Commonly reported side effects were primarily injection site pain and constipation. Data collection and analyzation is anticipated to be completed well before conference date

Recently approved mAbs targeting CGRP and CGRPR have shown promising results in the adult population, however, studies in the pediatric population are still underway. Preliminary results from our study indicate reduction in headache severity and frequency. As currently approved preventative therapies are limited in the pediatric population, continued investigation towards alternative agents is paramount to improve headache prevention in this group. This data will also be useful towards future long-term studies exploring the use of these agents in children.